OrbiMed’s Mustang Bio MBIO Stock Holding History

OrbiMed’s Portfolio MBIO Stock Details MBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-336	Closed	-$675K	–	145
2020 Q1	$675K	Hold	336	–	–	0.01%	138
2019 Q4	$1.03M	Buy	+336	New	+$769K	0.01%	131

Other funds holding MBIO

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

OrbiMed's MBIO Position: Q2 2020 in Review

OrbiMed sold out of Mustang Bio (MBIO) in Q2 2020, closing a stake of 336 shares — an estimated $675K sold.

OrbiMed first reported a position in MBIO in Q4 2019 and held it in 2 quarters. The position peaked at $1.03M in Q4 2019. 73 funds tracked by Wall St. Rank hold MBIO as of Q2 2020.

OrbiMed reported no remaining Mustang Bio position as of Q2 2020 after selling out during the quarter.
OrbiMed sold 336 Mustang Bio shares in Q2 2020, an estimated $675K.
OrbiMed first reported a position in Mustang Bio in Q4 2019 and held it in 2 quarters.
OrbiMed's Mustang Bio position peaked at $1.03M in Q4 2019.
73 funds tracked by Wall St. Rank held Mustang Bio as of Q2 2020.

Based on OrbiMed's 13F filing for Q2 2020, filed 14 Aug 2020.